Trial Profile
A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 09 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Jul 2013 Planned End Date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.